Anzeige
Mehr »
Login
Samstag, 29.03.2025 Börsentäglich über 12.000 News von 696 internationalen Medien
Ad-hoc-News: Wieder Verdopplung? Montag massiver Turnaround und komplette Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

JCN Newswire-Archiv vom 20.11.2024

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
20.11.24NaaS Technology Inc. Scores First Quarterly Profit, with Strategy Focused on EV Charging Services331- NaaS Technology Inc. Reports Q3 2024 Results, Achieving Positive Non-IFRS ProfitHONG KONG, Nov 20, 2024 - (ACN Newswire) - NaaS Technology Inc. (Nasdaq: NAAS), a U.S.-listed EV charging service provider...
► Artikel lesen
20.11.24HKTDC: BIP Asia Forum and Entrepreneur Day Returns in December354- Empowering SMEs and start-ups and reinforcing Hong Kong's status as an IT hub and Regional Intellectual Property Trading CentreHONG KONG, Nov 20, 2024 - (ACN Newswire) - The 14th Business of IP Asia...
► Artikel lesen
20.11.24Mitsubishi Heavy Industries, Ltd.: Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center556-- Selected for the Tokyo Metropolitan Government's Bureau of Industrial and Labor Affairs' Support Project for Early Social Implementation Aimed at Creating GX-Related Industries --- High-performance...
► Artikel lesen
20.11.24Eisai: Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan765TOKYO, Nov 20, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the amyotrophic lateral sclerosis (ALS) treatment "Rozebalamin for Injection25 mg" (mecobalamin) has been launched in Japan...
► Artikel lesen
20.11.24Eisai: Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements600TOKYO, Nov 20, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched fibroblast growth factor receptor (FGFR) selective tyrosine kinase inhibitor "TASFYGO Tablets 35mg" (generic...
► Artikel lesen